Review Article
Volume 9 Issue 2 - 2021
Chemotherapy-Related Neutropenia, Risks of Neutropenic Fever and Antibacterial Prophylaxis
Fawzia Ayedh Asiri*, Razan Mohammad Al-Alkami, Rahaf Mosfer Al-Ghamdi, Khlood Saif Alqahtani, Atheer Dhafer Almohammed and Nada Saeed Alhajeri
King Khalid University, Abha, Saudi Arabia
*Corresponding Author: Fawzia Ayedh Asiri, King Khalid University, Abha, Saudi Arabia.
Received: June 23, 2020; Published: January 30, 2021


Introduction: Most antineoplastic agent used in oncology are cytotoxic. Excessive amounts needed to treat cancer patients adversely affect myelopoiesis leading to severe and sometimes prolonged neutropenia, which may result in potentially fatal infection.

Aim of Work: In this review, we will discuss the last available evidence about the risk of neutropenic fever in patient treated with chemotherapy and the antibacterial agent to prevent the condition.

Methodology: We conducted a systematic search on PubMed search engine and Google Scholar search engine for all studies examining neutropenic febrile syndrome.

Conclusion: The predictor of neutropenic fever could be related to the patient, the disease, and the cytotoxic agent used. Female gender, concomitant active comorbidity negatively affecting patient’s performance as cardiovascular, renal, endocrine, or pulmonary conditions, higher body surface area, and bad nutritional status are associated with higher risk of neutropenic fever and its complication.

Antimicrobial prophylaxis aims to prevent or reduce the risk of neutropenic fever and its complication. It is not clear what is the optimal time for initiating is and discontinuing antibacterial prophylaxis due to lack of evidence. Gram-negative bacilli especially Pseudomonas aeruginosa are among most incriminated pathogens. Fluoroquinolone prophylaxis reduced the risk for all-cause mortality as well as infection-related mortality.

Keywords: Neutropenic Febrile Syndrome; Chemotherapy-Related Neutropenia; Risks of Neutropenic Fever; Prevention; Antimicrobial Agent with Chemotherapy


  1. Sickles EA., et al. “Clinical presentation of infection in granulocytopenic patients”. Archives of Internal Medicine 135 (1975): 715.
  2. Freifeld AG., et al. “Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america”. Clinical Infectious Diseases 52 (2011): e56.
  3. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 1 (2018).
  4. Taplitz RA., et al. “Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update”. Journal of Clinical Oncology 14 (2018): 1443-1453.
  5. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) (2017).
  6. Fosså SD., et al. “Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy”. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Co.
  7. Tjan-Heijnen VC., et al. “Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study” (2019).
  8. Timmer-Bonte JN., et al. “Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study”. Journal of Clinical Oncology 31 (2005): 7974-7984.
  9. Lyman GH., et al. “Risk models for predicting chemotherapy-induced neutropenia”. Oncologist 10 (2005): 427.
  10. Lyman GH., et al. “Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study”. Journal of Clinical Oncology 22 (2004): 4302.
  11. Voog E., et al. “Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system”. Journal of Clinical Oncology 18 (2000): 325.
  12. Schwenkglenks M., et al. “Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment”. Support Care Cancer 14 (2006): 901.
  13. Intragumtornchai T., et al. “A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin’s lymphoma”. Leuk Lymphoma3.4 (2000): 351-360.
  14. Gianni L., et al. “Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study”. Journal of Clinical 11 (1995): 2688-2699.
  15. Klastersky J., et al. “The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients”. Journal of Clinical Oncology 18 (2000): 3038.
  16. Von Minckwitz G., et al. “Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis”. European Journal of Cancer 4 (2009): 608-617.
  17. Blay JY., et al. “Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia”. Journal of Clinical Oncology 14 (1996): 636.
  18. Ray-Coquard I., et al. “Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy”. British Journal of Cancer 88 (2003): 181.
  19. Smith TJ., et al. “Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update”. Journal of Clinical Oncology 33 (2015): 3199.
  20. Pettengell R., et al. “Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study”. Support Care Cancer 16 (2008): 1299.
  21. Aapro MS., et al. “EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours”. European Journal of Cancer 42 (2006): 2433-2453.
  22. Leibovici L., et al. “Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions”. Cancer 107 (2006): 1743.
  23. Gafter-Gvili A., et al. “Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy”. Cochrane Database of Systematic Reviews 1 (2012): CD004386.
  24. Tomblyn M., et al. “Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective”. Biology of Blood and Marrow Transplantation 15 (2009): 1143.
  25. Taplitz RA., et al. “Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update”. Journal of Clinical Oncology 36 (2018): 3043.
  26. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version (2018).
  27. Bow EJ. “Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients”. Current Opinion in Infectious Diseases 24 (2011): 545.
  28. Wingard JR., et al. “Use of antibacterial prophylaxis in patients with chemotherapy-induced neutropenia”. Current Opinion in Hematology 19 (2012): 21.
  29. Ng ES., et al. “Fluoroquinolone prophylaxis against febrile neutropenia in areas with high fluoroquinolone resistance--an Asian perspective”. Journal of the Formosan Medical Association 109 (2010): 624.
  30. Alexander S., et al. “Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial”. The Journal of the American Medical Association 320 (2018): 995.
  31. Hakki M., et al. “Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients”. Clinical Infectious Diseases 68 (2019): 2045.
Citation: Fawzia Ayedh Asiri., et al. “Chemotherapy-Related Neutropenia, Risks of Neutropenic Fever and Antibacterial Prophylaxis”. EC Pharmacology and Toxicology 9.2 (2021): 44-49.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

April Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the April issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before May 04, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to